We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRLS Trellus Health Plc

0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 1,247,954 07:37:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 1.65p. Over the last year, Trellus Health shares have traded in a share price range of 1.65p to 9.20p.

Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £2.66 million. Trellus Health has a price to earnings ratio (PE ratio) of -0.42.

Trellus Health Share Discussion Threads

Showing 226 to 248 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
“You should be warned off this site“

What does one have to do to be deemed unsuitable for THIS site! Lol it’s like all the mentally ill and adult virgins in the UK got together and asked “where can we spend our days posting messages to each other?” My god, this place makes LSE look like royalty!

Hopefully back to 65p very soon here you would presume.
This has much further to go this week? 20p + by the end of this week?
Thanks James.
mikemine1 Sign up to the (free) InvestorMeetCompany website. The presentation can be accessed there.
Good presentation.
The Dr seems v impressive.
I added on Friday at 7.2p so well pleased.

I don't know how you guys get to the presentations. I've been all over Trellus's website and zilch. Got a link anybody?
An excellent webinar presentation, with the CEO exuding a high degree of knowledge, and importantly confidence in terms of delivery. And so it would appear that we can expect news flow accordingly.

Thus, it is justifiable to repeat, that with the changes made, including to the overall strategy, it's already having a positive effect and impact, and looks set to be transformative.

I have not got access to the full note -

Cash runway extended, multiple near term opps
Trellus Health PLC (TRLS:LON) | 7.2 -0.1 (-9.4%) | Mkt Cap: 11.7m

The incoming new management team at Trellus has acted swiftly to reduce cash burn, extending the runway to early 2025. The company is now transitioning to a revenue-generating business, with the first paying members enrolled post-period end and multiple near term commercial opportunities across its D2C and B2B2C offerings in the advanced stages of finalisation. These should unlock access to substantial patient populations, accelerating adoption of the platform, commercialisation and, ultimately, shareholder value.

Agree that valuation is low (below 2022F net cash) as there are >2 years’ runway for company to show some traction. So even if you only value the company as an option, it is a reasonably long-dated option.

Getting Dr Dubinsky into the CEO seat will surely increase the company’s credibility. Yet it is amazing how far off-track Trellus has gone in the last few months. On the May ImC call, then-CFO stated that the company would be profitable on a run-rate basis by end-23 and Singer was forecasting revenue of $11m (already cut from $18m) in 2023. Today, I see Singer has removed its 2023 forecasts, citing a lack of visibility.

jane deer
Insane valuation one to add to over the coming months even in this market


Agree unusual that small caps have cash and a rosey future with MCAP under cash. I’d say this should be 30-40p priced fairly.
Toady's Results highlight numerous and highly encouraging developments and provides a backdrop of very positive outlook and commentary.

Cash at the end of June equates to circa £21m and will last through and into 2025, and when compared to the current market cap of £13m, even the current cash outweighs the market cap by a significant margin!

It would appear the changes made, including to the overall strategy, is already having a positive impact, and looks set to be transformative.

Context - Gastroenterology is a key (top) business area for Takeda, with recently reported revenues of $1.8bn (270.4 billion yen) in their recent first quarter results -

Gastroenterology includes the management of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

Trellus health - Customized resilience roadmaps developed by experts, delivered by technology and, designed by a team dedicated to promoting health and wellness for people living with chronic conditions, starting with inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. The Trellus Approach is based on a scientifically validated method developed at the Mount Sinai Health System to improve one’s strength and confidence in managing a chronic condition, and ability to overcome adversity while dramatically improving outcomes at reduced cost.

The TrellusElevate™ Platform and mobile app connects the team, the tools and the technology needed to ensure all people living with a chronic condition have hope and thrive.

Part of the Trellus Health offering for healthcare providers and individuals includes medication adherence and the importance of disease monitoring, with a strategy to focus on both a Direct To Consumer model as well as a Business-to-Business model to expand their customer base, and to add further regional and national multi-year contracts with payers from 2023 onwards -

Readers will already appreciate that Dr Marla Dubinsky is a Trellus Health co-founder and became the CEO in July 2022.

The following recently caught my attention -

September 14, 2022

Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease Patients

SAN DIEGO, Sept. 14, 2022 /PRNewswire/ -- Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients. CDPATH is a personalized risk assessment tool that can be used in combination with a physician's clinical assessment to evaluate an adult patient's risk for developing serious complications of CD such as bowel strictures, internal penetrating disease, or non-perianal surgery within three years.

The CDPATH test is a result of a collaboration among Prometheus, MiTest Health LLC ("MiTest") and Takeda Pharmaceutical Company Limited ("Takeda"). MiTest defined and established the clinical relevance of the CDPATH model through an independent clinical study. Prometheus, a CLIA certified and CAP accredited laboratory, validated CDPATH and is the processing laboratory for the CDPATH program. Takeda will make CDPATH available for use by US-based physicians and offer the test free of charge to eligible patients, with the goal of supporting shared decision-making between patients and healthcare providers.

"This tool was developed to address a significant unmet need in the management of Crohn's disease," said Dr. Marla Dubinsky, who along with being a Co-inventor and Co-founder of MiTest Health, is also a Professor of Pediatrics and Medicine at the Icahn School of Medicine, Chief of Division of Pediatric Gastroenterology and Co-director of the Mount Sinai Susan and Leonard Feinstein IBD Clinical Center. "With CDPATH, we want to identify patients before they have severe disease and inform discussions with patients about the management of disease."

This partnership with Takeda, a pharmaceutical industry leader in the field of gastroenterology (GI), contributes to the Prometheus mission of enabling precision-guided patient care and improving disease outcomes.

Mike Walther, President of Prometheus Laboratories commented, "We are pleased to partner with Takeda to make CDPATH available to healthcare providers and their patients. Supporting the launch of CDPATH is yet another milestone among our strategic initiatives as we continue to provide innovative clinical lab services to guide care from disease interception through therapeutic optimization and monitoring."

"At Takeda, we are driven by the challenge of making a meaningful difference in the lives of patients with inflammatory bowel disease, and working with partners to provide solutions that can help transform their care," said Gamze Yüceland, Head, Gastroenterology Business Unit, Takeda Pharmaceuticals, U.S.A., Inc. "Offering CDPATH free of charge to eligible CD patients will help deliver an innovative tool to the community that can help inform and personalize CD management."

CDPATH integrates patient-specific serologic markers and genetic marker status, identified via a blood sample, with patient's CD characteristics to help predict a low, medium, and high risk for potentially developing serious CD complications over a three-year period. It is intended to be used in combination with a physician's clinical assessment. Healthcare providers will receive a CDPATH test report with a graphical risk profile that can then be used to facilitate discussions with patients.

CDPATH is only validated in, and can only be performed on, adult Crohn's disease patients (≥18 years old) diagnosed within the past ten (10) years, who have not experienced a Crohn's disease complication such as bowel strictures, internal penetrating disease, or non-perianal surgery (bowel resection or stricturoplasty).

CLIA: Clinical Laboratory Improvement Amendments; CAP: College of American Pathology

Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun.

Full release -

An interesting development, connections, and provides food for thought!

This will be snapped up IMHO
By my estimates, the market cap is still currently worth less than the cash element, even with todays notable share price improvement.
Over 11m shares traded in Trellus Health yesterday, which was a higher trade volume than in Legal & General!

One would assume that there will be accompanying holding announcements in due course, and perhaps something more. Time will tell.

At 7p mdown from 70p a passive investor will need a return of 10 times to get back what they invested, just to be flat. Anyone subscribing to the fundraise in May would have lost over 80% of their investment. Like Renalytix there appears to be no business acuman behind the idea and like Renalyix the stock market has been used as a money-raid and for no other reason.
And I note a larger jump in volume yesterday.
Notable volume today.
I also meant to add that EKF indicated their intention to launch a Calprotectin test this year. Fecal calprotectin (or faecal in the UK), is a marker of mucosal inflammation. The test can help physicians diagnose inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and differentiate them from irritable bowel syndrome (IBS).

Going forwards, Trellus intend to also address IBS, and I note a test for this is included in the indicated list of tests at EKF owned ADL Health laboratory in the US.

I note recently that some large players are actively interested or indeed already moving into the area of addressing chronic conditions.

I also note the following -

Congratulations from the entire Trellus community to our co-founder, Dr. Laurie Keefer for receiving the Distinguished Investigator Award for Women in Neurogastroenterology -

Recall that in September 2021 Trellus signed an agreement to provide an Inflammatory Bowel Disease ("IBD") demonstration programme for the Mount Sinai Health System.

Following enrolment, the demonstration programme will coordinate six months of active care management followed by a final programme report, expected to be available within 30 days of programme completion. This initial demonstration programme is expected to commence before the end of 2021 with conclusions from the final programme report expected in 2022.

One would assume that that final programme report must be getting quite close to publication.

Trellus not intending to sit on their laurels either though with todays announcement.
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock